The total investment amounts to approximately SEK 30.2 million and is structured in multiple tranches through directed share issues. Initial tranches have already been completed, with further investments expected in subsequent phases subject to regulatory timelines.

This transaction reflects ongoing cross-border collaboration between Nordic and Chinese stakeholders in the Life Science sector, in which Eurosin has been involved as an advisor in facilitating strategic cooperation.

Source: OncoZenge